GlobalRPh | Advanced v1.8 | Evidence review 2026-10-17

GlobalRPh Vancomycin Dosing and Bayesian AUC Calculator Advanced

Select Bayesian model-informed dosing or conventional first-order pharmacokinetic AUC estimation. Adult intermittent-infusion clinician decision support.

Adult intermittent IV vancomycin. The AUC24 400-600 mg*h/L target is based primarily on serious MRSA infections and an assumed broth-microdilution MIC of 1 mg/L. Do not automatically increase exposure above 600 solely to reach AUC/MIC 400, or reduce exposure solely because MIC is below 1.

* Fields marked with an asterisk are required for the selected workflow. Use a decimal point, for example 1.5; enter units with the unit selector, not in the number.

1. Dosing method and clinical workflow
Bayesian is preferred when a suitable population prior and reliable dose history are available. The conventional method uses one-compartment first-order equations. With two suitable post-infusion levels, it also reports a linear/log trapezoidal AUC cross-check; a trapezoidal estimate cannot be derived from no levels or one level without additional assumptions.
Select the intended AUC before calculating. The guideline range remains 400-600 when MIC is assumed to be 1 mg/L.
For empiric AUC/MIC interpretation, use MIC 1 unless a reliable broth-microdilution value is available.

Infusion times for generated regimens

Applies to generated future regimens and the exact-target reference. Entered administration-history and custom-regimen durations stay as entered.

Used only with dose-based infusion times; this choice does not affect the 10 mg/min policy.

View dose-based infusion times and administration reference
Dose-based infusion times
DoseInfusion duration
Up to and including 500 mg30 minutes (0.5 h)
More than 500 mg through 1,250 mg60 minutes (1 h)
More than 1,250 mg through 1,750 mg90 minutes (1.5 h)
More than 1,750 mg through 2,000 mg120 minutes (2 h)
More than 2,000 mg150 or 180 minutes (2.5 or 3 h), as selected above

The rate-based default uses at least 60 minutes and no faster than 10 mg/min, rounded up to the next 15 minutes. Dose-based times can be shorter or faster than that reference. Confirm that the selected times match the actual product labeling, the patient's infusion tolerance, and the applicable local policy. See the reviewed Hospira IV powder label and infusion equations and background.

Selected workflow: Bayesian population-model estimation will be used. No current dose or measured concentration is required for this pre-dose estimate.
2. Patient parameters
3. Current regimen and measured concentrations
Used to reconstruct regular dose history for Bayesian estimation. The first-dose workflow forces one dose.
Sampling-time convention: Enter elapsed hours from the start of the most recent infusion. For guideline-style two-level equation dosing, the first sample should be postdistributional, generally 1-2 hours after the infusion ends, and the second should be near the end of the interval.
4. Conventional PK assumptions and legacy options
Default 0.65 L/kg. This assumption is used for empiric and single-level conventional calculations; two-level workflows calculate Vd from concentrations.
5. Data review and optional model comparison

Review the administration record and sampling conditions. An unanswered item remains unverified. A confirmed discrepancy can prevent a calculation when the entered regular schedule or stable-PK assumptions are no longer valid.

New calculation